Hims & Hers CMO Sells Shares Amid Expansion into Testosterone and Peptides
Patrick Harrison Carroll, the Chief Medical Officer of Hims & Hers Health (ticker: HIMS), sold 10,201 shares on August 14 at $28.15 per share to satisfy tax obligations tied to restricted stock unit vesting. The transaction was part of a standard four-year service-based vesting schedule and did not indicate any change in the executive's long-term commitment or confidence in the company. Hims & Hers is expanding into more complex healthcare areas, including testosterone replacement therapy, which is projected to become its sixth U.S. specialty with over $100 million annual revenue. However, this expansion comes at a cost: CFO Yemi Okupe noted on an earnings call that gross margins may compress as the company diversifies. Investors are advised to focus on long-term growth potential despite short-term margin pressures and recent stock volatility.
Tickers: $HIMS
Topics: executive equity vesting restricted stock units SEC filing